Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00

Key Points

• Ultragenyx Pharmaceutical's price target has been reduced from $112.00 to $105.00 by Cantor Fitzgerald, yet the firm maintains an "overweight" rating on the stock, suggesting a potential upside of 292.01% from the current price.
• Wells Fargo has also downgraded its target for the stock significantly to $65.00, while other firms such as Guggenheim and HC Wainwright have positive ratings with targets ranging from $64.00 to $80.00.
• During recent trading, Ultragenyx shares fell by $2.14 to reach $26.79, marking a significant decrease compared to its 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) had its target price decreased by Cantor Fitzgerald from $112.00 to $105.00 in a research report released on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical's FY2025 earnings at ($5.19) EPS and FY2026 earnings at ($3.21) EPS.

Other research analysts have also issued research reports about the stock. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Wells Fargo & Company reduced their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. Morgan Stanley dropped their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Trading Down 1.0%

RARE traded down $0.29 during midday trading on Wednesday, hitting $27.54. The company had a trading volume of 1,527,932 shares, compared to its average volume of 2,607,080. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The firm's 50-day simple moving average is $33.32 and its 200-day simple moving average is $36.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.52) EPS. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the company. Creative Planning acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $454,000. Police & Firemen s Retirement System of New Jersey increased its holdings in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 34,592 shares of the biopharmaceutical company's stock worth $1,258,000 after buying an additional 2,458 shares during the last quarter. Geode Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock worth $62,291,000 after buying an additional 66,394 shares during the last quarter. S&CO Inc. increased its holdings in Ultragenyx Pharmaceutical by 24.7% during the second quarter. S&CO Inc. now owns 25,255 shares of the biopharmaceutical company's stock worth $918,000 after buying an additional 5,000 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $309,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.